333 related articles for article (PubMed ID: 9225644)
21. Mechanism of action and clinical effects of antiprogestins on the non-pregnant uterus.
Spitz IM; Robbins A
Hum Reprod Update; 1998; 4(5):584-93. PubMed ID: 10027612
[TBL] [Abstract][Full Text] [Related]
22. Effect of low-dose mifepristone administration on day 2 after ovulation on transcript profiles in implantation-stage endometrium of rhesus monkeys.
Ghosh D; Sharkey AM; Charnock-Jones DS; Smith SK; Sengupta J
Reproduction; 2009 Aug; 138(2):357-70. PubMed ID: 19439560
[TBL] [Abstract][Full Text] [Related]
23. Effect of low daily doses of mifepristone on ovarian function and endometrial development.
Danielsson KG; Swahn ML; Westlund P; Johannisson E; Seppälä M; Bygdeman M
Hum Reprod; 1997 Jan; 12(1):124-31. PubMed ID: 9043916
[TBL] [Abstract][Full Text] [Related]
24. Comparative effectiveness of three antiprogestins alone and in combination with anordiol in terminating pregnancy in the rat.
Dao B; Vanage G; Li XJ; Bardin CW; Koide SS
Contraception; 1997 Jan; 55(1):35-40. PubMed ID: 9013059
[TBL] [Abstract][Full Text] [Related]
25. Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486: a potential new contraceptive strategy.
Batista MC; Cartledge TP; Zellmer AW; Merino MJ; Axiotis C; Loriaux DL; Nieman LK
Am J Obstet Gynecol; 1992 Jul; 167(1):60-5. PubMed ID: 1442957
[TBL] [Abstract][Full Text] [Related]
26. Effects of a single post-ovulatory dose of RU486 on endometrial maturation in the implantation phase.
Gemzell-Danielsson K; Svalander P; Swahn ML; Johannisson E; Bygdeman M
Hum Reprod; 1994 Dec; 9(12):2398-404. PubMed ID: 7714164
[TBL] [Abstract][Full Text] [Related]
27. RU486: pharmacology and potential use in the treatment of endometriosis and leiomyomata uteri.
Murphy AA; Castellano PZ
Curr Opin Obstet Gynecol; 1994 Jun; 6(3):269-78. PubMed ID: 8038415
[TBL] [Abstract][Full Text] [Related]
28. Contraceptive efficacy of low doses of mifepristone.
Marions L; Danielsson KG; Swahn ML; Bygdeman M
Fertil Steril; 1998 Nov; 70(5):813-6. PubMed ID: 9806558
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of emergency contraception with gestrinone: a preliminary investigation.
Gao X; Wu E; Chen G
Contraception; 2007 Sep; 76(3):221-7. PubMed ID: 17707720
[TBL] [Abstract][Full Text] [Related]
30. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
Papanikolaou EG; Bourgain C; Kolibianakis E; Tournaye H; Devroey P
Hum Reprod; 2005 Jun; 20(6):1541-7. PubMed ID: 15705618
[TBL] [Abstract][Full Text] [Related]
31. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century.
Spitz IM
Contraception; 2010 Nov; 82(5):442-52. PubMed ID: 20933118
[TBL] [Abstract][Full Text] [Related]
32. Effect of levonorgestrel and mifepristone on endometrial receptivity markers in a three-dimensional human endometrial cell culture model.
Meng CX; Andersson KL; Bentin-Ley U; Gemzell-Danielsson K; Lalitkumar PG
Fertil Steril; 2009 Jan; 91(1):256-64. PubMed ID: 18206148
[TBL] [Abstract][Full Text] [Related]
33. RU 486: an overview of mifepristone and its potential applications.
Contracept Rep; 1993 May; 4(2):7-9. PubMed ID: 12286473
[TBL] [Abstract][Full Text] [Related]
34. Effect of mifepristone on uterine receptivity in guinea pigs.
Liu CQ; Wang ZX; Yuan Y
Acta Pharmacol Sin; 2002 Feb; 23(2):177-82. PubMed ID: 11866881
[TBL] [Abstract][Full Text] [Related]
35. [A new antiprogestational compound, mifepristone (RU-486)].
Parisi C; Steffe M
Patol Clin Ostet Ginecol; 1988; 16(4):291-4. PubMed ID: 12345008
[TBL] [Abstract][Full Text] [Related]
36. Post-coital contraception.
Haspels AA
IPPF Med Bull; 1988 Oct; 22(5):1-3. PubMed ID: 12281624
[TBL] [Abstract][Full Text] [Related]
37. Contraceptive efficacy of daily administration of 0.5 mg mifepristone.
Marions L; Viski S; Danielsson KG; Resch BA; Swahn ML; Bygdeman M; Kovâcs L
Hum Reprod; 1999 Nov; 14(11):2788-90. PubMed ID: 10548623
[TBL] [Abstract][Full Text] [Related]
38. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days.
Brown A; Cheng L; Lin S; Baird DT
J Clin Endocrinol Metab; 2002 Jan; 87(1):63-70. PubMed ID: 11788624
[TBL] [Abstract][Full Text] [Related]
39. Effects of daily low dose mifepristone on endometrial maturation and proliferation.
Cameron ST; Critchley HO; Thong KJ; Buckley CH; Williams AR; Baird DT
Hum Reprod; 1996 Nov; 11(11):2518-26. PubMed ID: 8981147
[TBL] [Abstract][Full Text] [Related]
40. Effects of a preovulatory single low dose of mifepristone on ovarian function.
van der Stege JG; Pahl-van Beest EH; Beerthuizen RJ; van Lunsen RH; Scholten PC; Bogchelman DH
Eur J Contracept Reprod Health Care; 2006 Jun; 11(2):104-8. PubMed ID: 16854683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
